Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated "Buy" by Sell-Side Analysts

Key Points

• Analyst sentiment is bullish: Eleven brokerages give Perspective Therapeutics an average “Buy” rating, with a consensus 12-month price target of $11.50 versus the stock’s recent $2.36 price.
• The stock has declined sharply: CATX was reported down 8.2%, trading below both its 50-day and 200-day moving averages, and remains well below its 12-month high of $6.16.
• Perspective Therapeutics remains a clinical-stage biotech: The company reported a quarterly loss of $0.22 per share but beat estimates, while institutional investors own 54.66% of its shares and its lead programs target cancers using precision radiopharmaceutical therapies.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) has received an average recommendation of "Buy" from the eleven brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $11.50.

A number of brokerages recently issued reports on CATX. Wedbush reissued an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, September 15th. Bank of America decreased their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating for the company in a research note on Friday, August 14th. BMO Capital Markets set a $11.00 price objective on shares of Perspective Therapeutics and gave the stock an "outperform" rating in a research report on Tuesday, August 18th. William Blair assumed coverage on shares of Perspective Therapeutics in a research report on Friday, September 18th. They issued an "outperform" rating for the company. Finally, BTIG Research reissued a "buy" rating on shares of Perspective Therapeutics in a research report on Friday, July 24th.

Institutional Trading of Perspective Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CATX. Abel Hall LLC acquired a new stake in Perspective Therapeutics during the 1st quarter worth approximately $49,000. Caitong International Asset Management Co. Ltd bought a new position in Perspective Therapeutics during the 4th quarter worth $84,000. Wealth Effects LLC lifted its holdings in shares of Perspective Therapeutics by 32.0% during the first quarter. Wealth Effects LLC now owns 33,000 shares of the company's stock worth $138,000 after buying an additional 8,000 shares in the last quarter. Taylor & Morgan Wealth Management LLC boosted its position in shares of Perspective Therapeutics by 127.6% in the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company's stock valued at $225,000 after acquiring an additional 37,000 shares during the period. Finally, Quantinno Capital Management LP bought a new stake in shares of Perspective Therapeutics in the first quarter valued at about $273,000. Institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Trading Down 8.2%

NYSEAMERICAN CATX opened at $2.36 on Wednesday. The stock has a 50-day simple moving average of $2.96 and a 200 day simple moving average of $3.43. Perspective Therapeutics has a 12 month low of $1.96 and a 12 month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The firm had revenue of $0.08 million during the quarter, compared to analysts' expectations of $0.09 million. As a group, equities analysts predict that Perspective Therapeutics will post -0.98 earnings per share for the current year.

About Perspective Therapeutics

Perspective Therapeutics, Inc is a clinical-stage radiopharmaceutical biotechnology company developing precision-targeted alpha therapies for cancer. The company's approach combines tumor-targeting molecules with radioactive isotopes to deliver highly focused radiation to cancer cells while limiting exposure to surrounding healthy tissue.

Perspective's proprietary VMT platform is designed to support both diagnostic imaging and therapeutic applications. Its lead programs include VMT-α-NET, an investigational therapy targeting somatostatin receptor 2 for patients with neuroendocrine tumors, and VMT01, an investigational program targeting melanocortin 1 receptor-expressing cancers, including certain metastatic melanomas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.